These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 27117182

  • 1. In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor Killing.
    Lehmann S, Perera R, Grimm HP, Sam J, Colombetti S, Fauti T, Fahrni L, Schaller T, Freimoser-Grundschober A, Zielonka J, Stoma S, Rudin M, Klein C, Umana P, Gerdes C, Bacac M.
    Clin Cancer Res; 2016 Sep 01; 22(17):4417-27. PubMed ID: 27117182
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.
    Oberst MD, Fuhrmann S, Mulgrew K, Amann M, Cheng L, Lutterbuese P, Richman L, Coats S, Baeuerle PA, Hammond SA.
    MAbs; 2014 Sep 01; 6(6):1571-84. PubMed ID: 25484061
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Molecular Imaging of Radiolabeled Bispecific T-Cell Engager 89Zr-AMG211 Targeting CEA-Positive Tumors.
    Waaijer SJH, Warnders FJ, Stienen S, Friedrich M, Sternjak A, Cheung HK, van Scheltinga AGTT, Schröder CP, de Vries EGE, Lub-de Hooge MN.
    Clin Cancer Res; 2018 Oct 15; 24(20):4988-4996. PubMed ID: 29980531
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine model.
    Cremasco F, Menietti E, Speziale D, Sam J, Sammicheli S, Richard M, Varol A, Klein C, Umana P, Bacac M, Colombetti S, Perro M.
    PLoS One; 2021 Oct 15; 16(1):e0241091. PubMed ID: 33406104
    [Abstract] [Full Text] [Related]

  • 10. Multi-Parameter Quantitative Imaging of Tumor Microenvironments Reveals Perivascular Immune Niches Associated With Anti-Tumor Immunity.
    Stoltzfus CR, Sivakumar R, Kunz L, Olin Pope BE, Menietti E, Speziale D, Adelfio R, Bacac M, Colombetti S, Perro M, Gerner MY.
    Front Immunol; 2021 Oct 15; 12():726492. PubMed ID: 34421928
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers.
    Teijeira A, Migueliz I, Garasa S, Karanikas V, Luri C, Cirella A, Olivera I, Cañamero M, Alvarez M, Ochoa MC, Rouzaut A, Rodriguez-Ruiz ME, Sanmamed MF, Klein C, Umaña P, Ponz M, Bacac M, Melero I.
    Theranostics; 2022 Oct 15; 12(3):1373-1387. PubMed ID: 35154495
    [Abstract] [Full Text] [Related]

  • 13. Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody.
    Augsberger C, Hänel G, Xu W, Pulko V, Hanisch LJ, Augustin A, Challier J, Hunt K, Vick B, Rovatti PE, Krupka C, Rothe M, Schönle A, Sam J, Lezan E, Ducret A, Ortiz-Franyuti D, Walz AC, Benz J, Bujotzek A, Lichtenegger FS, Gassner C, Carpy A, Lyamichev V, Patel J, Konstandin N, Tunger A, Schmitz M, von Bergwelt-Baildon M, Spiekermann K, Vago L, Jeremias I, Marrer-Berger E, Umaña P, Klein C, Subklewe M.
    Blood; 2021 Dec 23; 138(25):2655-2669. PubMed ID: 34280257
    [Abstract] [Full Text] [Related]

  • 14. CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1.
    Osada T, Patel SP, Hammond SA, Osada K, Morse MA, Lyerly HK.
    Cancer Immunol Immunother; 2015 Jun 23; 64(6):677-88. PubMed ID: 25742933
    [Abstract] [Full Text] [Related]

  • 15. A mouse/human-chimeric bispecific antibody reactive with human carcinoembryonic antigen-expressing cells and human T-lymphocytes.
    Kuwahara M, Kuroki M, Arakawa F, Senba T, Matsuoka Y, Hideshima T, Yamashita Y, Kanda H.
    Anticancer Res; 1996 Jun 23; 16(5A):2661-7. PubMed ID: 8917366
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody.
    Osada T, Hsu D, Hammond S, Hobeika A, Devi G, Clay TM, Lyerly HK, Morse MA.
    Br J Cancer; 2010 Jan 05; 102(1):124-33. PubMed ID: 19953093
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids.
    Gonzalez-Exposito R, Semiannikova M, Griffiths B, Khan K, Barber LJ, Woolston A, Spain G, von Loga K, Challoner B, Patel R, Ranes M, Swain A, Thomas J, Bryant A, Saffery C, Fotiadis N, Guettler S, Mansfield D, Melcher A, Powles T, Rao S, Watkins D, Chau I, Matthews N, Wallberg F, Starling N, Cunningham D, Gerlinger M.
    J Immunother Cancer; 2019 Apr 15; 7(1):101. PubMed ID: 30982469
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.